Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Mind Medicine Inc (MMED.NE)
Mind Medicine Inc (MMED.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 FinancialNewsMedia - Wed Jul 26, 7:45AM CDT

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.7300 (+12.31%)
MMED.NE : 4.9100 (-2.77%)
CYBN : 0.5500 (+12.24%)
CMPS : 7.86 (-1.26%)
SEEL : 0.1629 (-14.26%)
MNMD : 3.61 (-2.43%)
NUMIF : 0.1363 (-4.08%)
NUMI.TO : 0.1800 (-5.26%)
MindMed Reports First Quarter 2023 Financial Results and Business Highlights Business Wire - Thu May 4, 3:02PM CDT

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy Business Wire - Tue May 2, 7:00AM CDT

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
INCY : 58.10 (-1.21%)
SGEN : 213.70 (+3.54%)
PFE : 32.69 (-0.49%)
FBRX : 0.7700 (-2.04%)
JAZZ : 131.75 (-0.74%)
ALC : 78.25 (-0.15%)
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update Business Wire - Mon May 1, 3:01PM CDT

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
MindMed to Participate in May Investor Conferences Business Wire - Wed Apr 26, 6:00AM CDT

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting Business Wire - Tue Apr 18, 3:15PM CDT

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
INCY : 58.10 (-1.21%)
BMY : 58.90 (-0.30%)
SGEN : 213.70 (+3.54%)
FBRX : 0.7700 (-2.04%)
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD) Business Wire - Fri Apr 14, 6:00AM CDT

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary Business Wire - Thu Apr 13, 6:00AM CDT

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
CARM : 3.94 (-1.01%)
MODL : 30.07 (-0.20%)
MindMed Reports Full Year 2022 Financial Results and Business Highlights Business Wire - Thu Mar 9, 3:02PM CST

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)
MindMed to Participate in March Investor Conferences Business Wire - Tue Feb 28, 6:30AM CST

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MMED.NE : 4.9100 (-2.77%)
MNMD : 3.61 (-2.43%)

Barchart Exclusives

2 Small-Cap Tech Stocks for Your September Watchlist Barchart - 32 minutes ago
Small-cap stocks can be highly rewarding for investors, as they generally have greater growth potential than their large-cap rivals. Here are two consistently profitable small-cap names with solid growth prospects. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot